Ask AI
ProCE Banner Activity

Closing Gaps in LDL-C Control: Treatment Intensification and Emerging PCSK9 Options

Clinical Thought

Despite advances in lipid-lowering therapies, many patients with atherosclerotic cardiovascular disease remain above recommended LDL-C thresholds, increasing their risk of cardiovascular events. Explore evidence supporting timely treatment intensification, strategies for overcoming barriers to LDL-C goal attainment, and the evolving role of PCSK9-targeted therapies in optimizing lipid management and reducing cardiovascular risk.

Released: October 30, 2026

Continue Activity View Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by educational funding provided by Amgen and Novartis Pharmaceuticals Corporation.

Amgen

Novartis Pharmaceuticals Corporation

Target Audience

This educational activity is intended for internal medicine physicians, nurse practitioners, and physician associates who care for patients with ASCVD.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify the role of elevated LDL-C as a causal driver of ASCVD progression and residual cardiovascular risk, even in optimally treated patients

Financial Disclosures

Primary Author

Ty J. Gluckman, MD, MHA, has no relevant financial relationships to disclose.

Additional Disclosures

Generative artificial intelligence (AI) tools were used for drafting educational content and drafting assessment question(s) and/or rationale(s). All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.